Position in URGN
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$40,408,126
+$34,774,007 QoQ
Shares Held
2,247,393
+695.8% QoQ
Ownership
4.61%
of shares outstanding
% of Portfolio
2.56%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2025
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in URGN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Kynam Capital Management, LP holds $1,494,846,229 across 33 Biotechnology names. URGN ranks #11 (2.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | SNDX |
Syndax Pharmaceuticals Inc
|
8,050,959 | $188,070,402 | |
| 2 | CLDX |
Celldex Therapeutics, Inc.
|
5,840,567 | $185,262,785 | |
| 3 | PCVX |
Vaxcyte, Inc.
|
2,922,335 | $169,816,886 | |
| 4 | COGT |
Cogent Biosciences, Inc.
|
4,037,331 | $155,396,870 | |
| 5 | VERA |
Vera Therapeutics, Inc.
|
3,398,224 | $136,710,551 | |
| 6 | BEAM |
Beam Therapeutics Inc.
|
3,682,185 | $87,746,468 | |
| 7 | CTMX |
CytomX Therapeutics, Inc.
|
15,013,093 | $70,561,537 | |
| 8 | TVTX |
Travere Therapeutics, Inc.
|
1,569,018 | $46,615,524 |
All Filings in URGN
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $40,408,126 | 2,247,393 | Shares | Sole | 2026-05-15 | |
| 2025-09-30 | $5,634,119 | 282,412 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $8,995,050 | 656,573 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $276,500 | 25,000 | Shares | Sole | 2025-05-15 | |
| No filing history on record for this holder in this stock. | ||||||